Microbot Medical (MBOT) Stock Price
Microbot Medical Price
Over the last 9 years Microbot Medical grew revenue by 2.6% annually, reaching 117,000.00 USD. For Microbot Medical, the net margin of -31,123.9% is down versus -1,746.8% a few years ago. The consensus 12-month price target for Microbot Medical is 4.00 USD, about 257.1% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Microbot Medical stock price
Microbot Medical business model & stock analysis
Frequently asked questions about Microbot Medical
Microbot Medical Inc's business model focuses on the development and commercialization of innovative transformational robotic solutions in the medical industry. The company specializes in creating miniature robots that can assist in minimally invasive surgeries, targeted drug delivery, and targeted endotherapy procedures. Microbot Medical Inc utilizes its proprietary technologies, including its Microbot Swarm system and ViRob robotic platform, to address critical unmet needs in various medical specialties. With its advanced robotic solutions, Microbot Medical Inc aims to improve patient outcomes, enhance surgical procedures, and provide physicians with more precise and efficient tools for diagnosis and treatment in the medical field.
Microbot Medical Inc is primarily active in the medical technology industry. As a cutting-edge company, Microbot Medical specializes in the development and commercialization of robotic technologies focused on improved medical procedures and treatments. With its innovative product portfolio, Microbot Medical aims to revolutionize various medical fields such as urology, neurology, and cardiovascular healthcare. Through its dedication to technological advancements and industry collaborations, Microbot Medical strives to provide healthcare professionals and patients with breakthrough solutions that enhance overall medical outcomes.
The main competitors of Microbot Medical Inc in the market include companies such as Medtronic, Intuitive Surgical, and Johnson & Johnson.
Microbot Medical Inc is a leading medical device company specializing in the development of transformational micro-robotic technologies. Established in 2010, Microbot Medical Inc aims to improve patient outcomes through the development of innovative robotic platforms designed for minimally invasive surgeries and targeted therapies. The company's cutting-edge technologies utilize advanced engineering and robotics to address significant unmet medical needs in various medical fields, including urology, gastroenterology, and ENT (ear, nose, and throat). With its commitment to revolutionizing medical interventions, Microbot Medical Inc continues to push boundaries in the field of robotic medicine, creating new possibilities for improved patient care.
Microbot Medical Inc has achieved several significant milestones. Firstly, the company successfully developed and received regulatory clearance for its innovative robotic technologies in the medical industry. Additionally, Microbot Medical Inc has made notable advancements in the fields of urology, neurology, and gastrointestinal procedures. The company has also successfully completed important clinical studies and collaborations with leading medical institutions. Moreover, Microbot Medical Inc has secured intellectual property rights for its proprietary technologies, which strengthens its position in the market. These milestones demonstrate the company's dedication to improving healthcare outcomes and solidify its reputation as a leader in the medical robotics field.
Microbot Medical Inc is primarily present in the United States, Israel, and Europe. This company, specializing in micro-robotics technologies, operates in multiple regions to distribute their innovative medical devices and solutions. Microbot Medical Inc's presence in these countries and regions enables them to reach a significant market and collaborate with leading medical institutions, professionals, and industry experts. By establishing a global footprint, Microbot Medical Inc aims to enhance patient outcomes and revolutionize the field of medical robotics.
Microbot Medical Inc represents values of innovation, advancement, and patient-centric healthcare solutions. With a strong corporate philosophy aimed at addressing unmet medical needs, Microbot Medical Inc is dedicated to developing and commercializing transformative robotic technologies. By combining novel engineering with medical expertise, the company aims to improve patient outcomes, reduce healthcare costs, and enhance overall quality of life. Microbot Medical Inc strives to empower physicians and healthcare professionals with cutting-edge tools and solutions, all while prioritizing patient safety and well-being.
Analysts currently set an average price target of 4.00 USD for the Microbot Medical stock (median: 4.00 USD), implying +257.1 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Microbot Medical stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Microbot Medical to generate revenue of 841,333.00 USD and earnings per share of -0.06 USD.
Converted at the current exchange rate, the Microbot Medical share trades at 1.00 EUR (1.12 USD).
The Microbot Medical share (MBOT) is listed on 4 stock exchanges, including: NASDAQ (MBOT), Frankfurt (CY9D.F), München (CY9D.MU), Düsseldorf (CY9D.DU).
Microbot Medical Inc is a leading company in the development and commercialization of miniature robots for medical applications. The company is based in Israel and also has branches in the USA.
The expected revenue of Microbot Medical is 841,333.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Microbot Medical is -4.21 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Microbot Medical is currently -17.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Microbot Medical stock.
The price-to-sales ratio (P/S) of Microbot Medical is currently 89.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Microbot Medical stock.
The Eulerpool Quality Score for Microbot Medical is 2/10.
The ISIN of Microbot Medical is US59503A2042. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Microbot Medical is A2N5AS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Microbot Medical is MBOT. The ticker symbol is used to trade Microbot Medical shares on the stock exchange.
Microbot Medical stock
Microbot Medical Peer Group
Microbot Medical Ticker
Microbot Medical FIGI
All fundamentals and in-depth analysis of Microbot Medical
Our stock analysis for Microbot Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Microbot Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.